CHICAGO, Feb. 8, 2018 /PRNewswire/ -- CME Group today
announced that Chairman Emeritus Leo
Melamed will retire from the CME Group Board of Directors at
the conclusion of his current term in May 2018. Following his
retirement, Melamed will serve as a consultant to the company for
the next two years. After that time, Melamed will continue to
retain his title as Chairman Emeritus.
"On behalf of the CME Group Board and Management Team, we
sincerely thank Leo Melamed for his
decades of service to our company and our industry," said CME Group
Chairman and Chief Executive Officer Terry
Duffy. "Leo's invention of financial futures and
pioneering of electronic trading shaped the financial markets as we
know them today, and his contributions will continue to have an
impact in the future. We wish him well and look forward to
working with him as a consultant."
"Bringing the CME Group from butter and eggs to a financial
institution has been a work of love," said Melamed. "I offer
my thanks to all the CME officials, board members, and employees
over the years, without whose efforts it could not have been
accomplished. I also want to thank Chairman and CEO
Terry Duffy for his outstanding
leadership, and wish him and the Board continued success."
Melamed is recognized as the founder of financial futures and
introduced the International Monetary Market in 1972. He has
served as Chairman Emeritus of CME Group since 1997 and as a board
member since 1967. Melamed was CME Chairman of the Board from
1968 until 1976 and held various board leadership positions over
the last three decades. He also played a leading role in the
development of the CME Globex electronic trading system in
1992.
Melamed currently serves as Chairman and CEO of Melamed &
Associates, a global consulting group, and as advisor to the
National Futures Association, the International Advisory Council of
the CSRC in China, and Leap
Innovations. He serves on the board of overseers of the
Becker Friedman Institute of the University of
Chicago, and as a director of The Chicago Council on Global
Affairs. Melamed is a published author of several books and
the recipient of multiple awards around the world. He holds
Doctor of Letters distinctions from the University of Illinois, Loyola
University, DePaul University,
the Tokyo based Waseda University, and a Doctor of Humane Letters
from Sacred Heart University.
As the world's leading and most diverse derivatives marketplace,
CME Group (www.cmegroup.com) is where the world comes to manage
risk. CME Group exchanges offer the widest range of global
benchmark products across all major asset classes, including
futures and options based on interest rates, equity
indexes, foreign exchange, energy, agricultural
products and metals. Around the world, CME Group
brings buyers and sellers together through its CME Globex®
electronic trading platform. CME Group also operates one of
the world's leading central counterparty clearing providers
through CME Clearing, which offers clearing and settlement
services across asset classes for exchange-traded and
over-the-counter derivatives. CME Group products and services
ensure that businesses around the world can effectively manage risk
and achieve growth.
CME Group, the Globe logo, CME, Chicago Mercantile Exchange,
Globex and E-mini are trademarks of Chicago Mercantile Exchange
Inc. CBOT, Chicago Board of
Trade, KCBT and Kansas City Board
of Trade are trademarks of Board of Trade of the City of Chicago, Inc. NYMEX, New York
Mercantile Exchange and ClearPort are trademarks of New York
Mercantile Exchange, Inc. COMEX is a trademark of Commodity
Exchange, Inc. Dow Jones, Dow Jones Industrial Average,
S&P 500 and S&P are service and/or trademarks of Dow Jones
Trademark Holdings LLC, Standard & Poor's Financial Services
LLC and S&P/Dow Jones Indices LLC, as the case may be, and have
been licensed for use by Chicago Mercantile Exchange Inc. All
other trademarks are the property of their respective
owners.
CME-G
View original
content:http://www.prnewswire.com/news-releases/cme-group-announces-retirement-of-leo-melamed-300595989.html
SOURCE CME Group